Baird cuts Xenon Pharmaceuticals price target to $90
Baird maintained an Outperform rating on Xenon Pharmaceuticals and cut its price target to $90.00 from $97.00, per Benzinga via TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.